InvestmentJul 2, 2026, 06:26 AM
Elicio Therapeutics Prices $15M Registered Direct Offering
AI Summary
Elicio Therapeutics, Inc. announced the pricing of a registered direct offering, expecting to raise approximately $15 million in gross proceeds. The company will issue 4,380,313 shares of common stock at $3.43 per share to institutional investors. The net proceeds will be used to fund the planned Phase 1 clinical development of ELI-002 7P in metastatic PDAC, as well as for pipeline development, working capital, and general corporate purposes.
Key Highlights
- Elicio Therapeutics priced a registered direct offering of 4,380,313 shares of common stock.
- The offering is expected to generate gross proceeds of approximately $15 million.
- Each share of common stock was sold at an offering price of $3.43.
- Proceeds will primarily fund Phase 1 clinical development of ELI-002 7P in metastatic PDAC.
- Funds will also support Elicio's pipeline, platform, working capital, and general corporate purposes.
- The offering is expected to close on or about July 6, 2026.
Price Impact
More from ELTX